Deferasirox
Home / API - Commercial / Deferasirox
CAS No.
201530-41-8
Therapeutic Category
- Chelating Agent
Innovator Brand
EXJADE , JADENU
GMP
Available
DMF
Not Available
Filed
Under Filing
Sample
Available
Indication
Exjade (deferasirox) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. In these patients, exjade has been shown to reduce liver iron concentration and serum ferritin levels.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.